obtained in three patients administered pefloxacin for 15-30 days. Berthoux et al.
Introduction water ad libitum. In all rats, adriamycin ( 7 mg/kg) was administered intravenously via a superficial femoral vein
The use of pefloxacin as a possible definitive treatment under light ether anaesthesia. for idiopathic nephrotic syndrome, either minimalThe rats were divided into two groups: group A (n=20) given only water ad libitum served as the control group and change nephropathy (MCN ) or focal segmental group B (n=19) was given pefloxacin (per drinking solution) glomerulosclerosis (FSGS ), was first proposed by at an average dose of 150 mg/kg beginning at day zero. All performed to evaluate the effect of pefloxacin on urinary protein excretion [14] . The protocol of this prior study, however, differed from the one we had Results chosen. Female rats were used whereas we studied male rats and the dose of intravenous adriamycin was Table 1 shows the results obtained. As expected, all 5 mg/kg compared to the 7 mg/kg we employed. the rats developed nephrotic range proteinuria as of Furthermore, we administered pefloxacin begining on day 7. Mean serum creatinine (0.57±0.08 and the day of injection of adriamycin. In contrast, in the 0.6±0.08 mg/dl ) and mean serum albumin ( 2.37±0.45 study of Zima [14 ] , administration of pefloxacin was and 2.68±0.27 g/dl ) did not differ between the two only started 3 weeks after the injection of adriamycin. groups. The only significant difference in protein-Proteinuria was then determined at weeks 3 and 6. uria was evident at day 7, being 423±656 vs Pefloxacin was not able to decrease established pro-173±78 mg/day in groups A and B respectively teinuria in nephrotic rats. Nevertheless, compared to (P<0.02). Thereafter, proteinuria in group B increased the untreated group, it prevented a further increase in and similar levels of protein excretion were seen at protein excretion during the 3 weeks of its administradays 14, 21 and 28.
tion, suggesting a sustained beneficial effect. The Mortality rates and percentage delta decrease in difference from our results may be explained by the body weight were similar between groups (results not fact that we employed male rats which had been given shown [10 ] , and oversecretion of interleukin-1 [11 ] . Pefloxacin has been shown the drug, 22 of whom had either MCN or FSGS, usually steroid resistant. The overall response rate to possess immunomodulatory properties. In vitro, an antiproliferative effect on lymphocytes and monocytes (partial or complete remission) was 26.9%. Although this response rate might be considered acceptable under has been demonstrated [12 ] . The drug increases interleukin-2 mRNA but decreases Il-2 receptor certain conditions, the indication must consider the high incidence of severe effects [3, 4] . Our results in concentration [13] . A rational explanation could therefore be given for a beneficial effect of pefloxacin in this particular experimental model, do not support the notion that pefloxacin is a useful antiproteinuric drug. MCN/FSGS.
In its early stages, adriamycin-induced nephrotic Although it is difficult to extrapolate animal data to humans, in view of the presently published clinical syndrome in the rat, the animal model we used, resembles MCN in the human, both biochemically and reports, the use of pefloxacin as a first-line treatment of the nephrotic syndrome in MCN/FSGS cannot be morphologically. In a preliminary experiment [8] , findings seemed to suggest an antiproteinuric effect of recommended. pefloxacin at a dose of 150 mg/kg. However, a similar reduction of protein excretion was found by vitamin C References (the ascorbate vehicle of pefloxacin) at a dose of 7 mg/kg. To further explore the effect of pefloxacin, proteinuria at day 7. Only one other animal study on
